C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 14.85 USD 0.54% Market Closed
Market Cap: 360.3m USD
Have any thoughts about
CVRx Inc?
Write Note

CVRx Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CVRx Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
C
CVRx Inc
NASDAQ:CVRX
Pre-Tax Income
-$41.1m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Pre-Tax Income
$2B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
3%
Boston Scientific Corp
NYSE:BSX
Pre-Tax Income
$2.2B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
36%
Stryker Corp
NYSE:SYK
Pre-Tax Income
$4.2B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
Pre-Tax Income
$6.8B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Pre-Tax Income
$2.4B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

CVRx Inc
Glance View

Market Cap
359.4m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
11 USD
Overvaluation 26%
Intrinsic Value
Price
C

See Also

What is CVRx Inc's Pre-Tax Income?
Pre-Tax Income
-41.1m USD

Based on the financial report for Dec 31, 2023, CVRx Inc's Pre-Tax Income amounts to -41.1m USD.

What is CVRx Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-43%

Over the last year, the Pre-Tax Income growth was 1%. The average annual Pre-Tax Income growth rates for CVRx Inc have been -43% over the past three years .

Back to Top